Alerts will be sent to your verified email
Verify Email
SHILPAMED
|
Shilpa Medicare
|
Aarti Pharmalabs
|
Supriya Lifescience
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Number of ANDA's Filed in USA
|
30.0 . | n/a | n/a |
|
Number of ANDA's Approved By USFDA
|
17.0 . | n/a | n/a |
|
Number of ANDA's Filed in Europe
|
83.0 | n/a | n/a |
|
US DMF Filings
|
49.0 . | n/a | n/a |
|
R&D as a % of Total Sales
|
3.76 % | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
3.31 % | 9.05 % | 23.4 % |
|
5yr average Equity Multiplier
|
1.62 | 1.39 | 1.25 |
|
5yr Average Asset Turnover Ratio
|
0.37 | 0.58 | 0.68 |
|
5yr Avg Net Profit Margin
|
5.49 % | 8.95 % | 25.52 % |
|
Price to Book
|
2.62 | 3.14 | 5.07 |
|
P/E
|
42.52 | 30.03 | 29.59 |
|
5yr Avg Cash Conversion Cycle
|
92.76 Days | 94.46 Days | -10.96 Days |
|
Inventory Days
|
108.8 Days | 94.9 Days | 56.1 Days |
|
Days Receivable
|
118.16 Days | 94.46 Days | 57.43 Days |
|
Days Payable
|
123.42 Days | 76.47 Days | 113.66 Days |
|
5yr Average Interest Coverage Ratio
|
3.59 | 12.05 | 60.74 |
|
5yr Avg ROCE
|
5.94 % | 12.13 % | 30.51 % |
|
5yr Avg Operating Profit Margin
|
17.75 % | 15.5 % | 36.15 % |
|
5 yr average Debt to Equity
|
0.43 | 0.16 | 0.06 |
|
5yr CAGR Net Profit
|
-11.93 % | n/a | 8.75 % |
|
5yr Average Return on Assets
|
2.0 % | 6.11 % | 17.81 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
40.13 % | 43.1 % | 68.3 % |
|
Share Pledged by Promoters
|
8.73 % | 0.01 % | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-9.88 % | -2.88 % | 0.06 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
5.15 % | -4.02 % | -1.71 % |
|
Shilpa Medicare
|
Aarti Pharmalabs
|
Supriya Lifescience
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|